Oxurion Receives Transparency Notifications from Fidelity Management & Research Company LLC and Novartis Pharma AG
18 March 2022 - 5:00AM
Oxurion Receives Transparency Notifications from Fidelity
Management & Research Company LLC and Novartis Pharma AG
Leuven,
Belgium, Boston, MA,
US - March
17, 2022 –
07.00
PM CET – Oxurion
NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, with clinical stage assets in vascular
retinal disorders, today announced that, pursuant to Belgian
transparency legislation1, it had received two transparency
notifications following the closing of its private placement, which
was announced on March 7, 2022.
Oxurion received a transparency notification
dated March 14, 2022, from Fidelity Management & Research
Company LLC, indicating that, by virtue of an acquisition of shares
on March 7, 2022, through the private placement, it had acquired
3,128,819 common shares, which represents 6.7% of Oxurion’s voting
rights, and thus crossed the 5% threshold (the “Fidelity
Notification”).
Oxurion also received a transparency
notification dated March 15, 2022, from Novartis Pharma AG and
Novartis AG, which confirmed Novartis Pharma AG’s holding of
2,177,226 common shares, which as a result of the private placement
now represents 4.7% of Oxurion’s voting rights, and thereby also
crossed the 5% threshold (downwards) (the “Novartis
Notification”).
Content of the Fidelity
NotificationReason of the notificationsAcquisition or
disposal of voting securities or voting rights.
Notifications byA parent undertaking or a
controlling person.
Persons subject to the notification
requirement
Date on which the threshold is crossed7 March
2022
Threshold that is crossed5%
Denominator46,628,892
Notified detailsSee Annex 1.
Chain of controlled undertakings through which
the holding is effectively heldFidelity Management & Research
Company LLC is controlled by FMR LLC. FMR LLC is not a controlled
entity.
Content of the
Novartis Notification Reason of
the notificationsPassive crossing of a threshold.
Notifications byA parent undertaking or a
controlling person.
Persons subject to the notification
requirement
Date on which the threshold is crossed7 March
2022
Threshold that is crossed5%
Denominator46,628,892
Notified detailsSee Annex 2.
Chain of controlled undertakings through which
the holding is effectively heldNovartis Pharma AG is a wholly-owned
direct subsidiary of Novartis AG.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company
developing next generation standard of care ophthalmic therapies,
which are designed to better preserve vision in patients with
retinal vascular disorders including diabetic macular edema (DME),
the leading cause of vision loss in diabetic patients worldwide as
well as other conditions, including wet age-related macular
degeneration (wet AMD) and macular edema following retinal vein
occlusion (ME-RVO). Oxurion is aiming to build a leading global
franchise in the treatment of retinal vascular disorders based on
the successful development of its two novel therapeutics. THR-149
is a potent plasma kallikrein inhibitor being developed as a
potential new standard of care for the 40-50% of DME patients
showing suboptimal response to anti-VEGF therapy. THR-687 is a
highly selective pan-RGD integrin antagonist that is being
developed as a potential first line therapy for DME patients as
well as wet AMD and potentially ME-RVO. Oxurion is headquartered in
Leuven, Belgium, with corporate operations in Boston, MA. More
information is available at www.oxurion.com.
For more information, please contact:
Oxurion NVTom GraneyChief Executive OfficerTel:
+32 16 75 13 10tom.graney@oxurion.com Michaël
DillenChief Business OfficerTel: +32 479 783
583michael.dillen@oxurion.com |
EUMEDiSTRAVA ConsultingDavid
Dible/ Sylvie Berrebi/Frazer HallTel: +44 20 7638
9571oxurion@medistrava.com
USWestwicke, an ICR
CompanyChristopher BrinzeyTel: +1 617 835
9304chris.brinzey@westwicke.com |
ANNEX 1
ANNEX 2
1 Article 14, first paragraph, of the Law of 2 May 2007 on
disclosure of major holdings.
- PR_Oxurion_Transparency Notification (ENG)_20220317
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From Apr 2024 to May 2024
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From May 2023 to May 2024